Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-06-14 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
The Latest Findings From CMTMe, a 'Real-World' Digital Lifestyle Study on Charcot-Marie-Tooth Diseases ('CMTs'), to be Presented at the 2023 Peripheral Nerve Society ('PNS') Annual Meeting
Regulatory Filings Classification · 1% confidence The document is a press release dated June 14th, 2023, announcing that new findings from a study ('CMT&Me') will be presented at the upcoming Peripheral Nerve Society ('PNS') Annual Meeting in June 2023. It details the titles and sessions for two poster presentations. This type of announcement, which informs the market about the presentation of scientific or clinical data at a conference, is typically classified as a general regulatory announcement or a specific type of investor communication. Since it is not a full report (10-K, IR), an earnings release (ER), or a formal presentation (IP), and it is a specific announcement about data dissemination, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, or potentially an Investor Presentation (IP) if it were the presentation itself. Given the short length (3837 chars) and the focus on announcing *where* data will be presented rather than providing the data itself, RNS is the most appropriate fallback for a non-standard announcement.
2023-06-14 English
Les derniers résultats de CMTMe, une étude digitale évaluant le mode de vie des patients atteints des maladies de Charcot-Marie-Tooth (CMTs), seront présentés au Congrès Annuel 2023 de la Peripheral N
Regulatory Filings Classification · 1% confidence The document is a press release dated June 14, 2023, announcing that new results from the 'CMT&Me' digital study will be presented as posters at the upcoming 2023 Annual Congress of the Peripheral Nerve Society (PNS). It details the titles of the posters and the session times at the conference. This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is an announcement related to scientific/clinical data presentation at a professional meeting. While it contains some business context, the primary focus is the presentation of study results at a specific external event (a medical congress). This type of announcement, which is essentially a regulatory/corporate update about scientific dissemination, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate communication, or potentially as a type of Investor Presentation (IP) if it were the presentation itself, but since it's an announcement *about* presentations, RNS is the most appropriate fallback for non-standard corporate news.
2023-06-14 French
Information relative au nombre total de droits de vote et d'actions composant le capital social et à la valeur nominale des actions
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content is the official announcement of the total number of voting rights and shares comprising the share capital, as required by French commercial code (Article L.233-8 II) and AMF regulations (Article 223-16). This type of mandatory disclosure regarding the share count and voting rights is a specific regulatory update. While it touches upon capital structure changes (reduction of nominal value), the core purpose is the periodic disclosure of the total share count. This fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Given the specific nature of reporting the total number of shares and voting rights, which is a common requirement related to capital structure, 'CAP' is a strong candidate. However, the document also details a capital reduction based on a prior shareholder resolution. Since the primary focus is the official count update mandated by regulation, and it details changes related to capital structure (conversions, BSAE exercises, and nominal reduction), 'CAP' (Capital/Financing Update) is the most precise fit among the options, as it directly relates to the company's capital structure reporting. It is not a full financial report (10-K, IR) or a simple announcement of a report (RPA).
2023-06-13 French
Pharnext supports and participates in the First European Charcot-Marie-Tooth disease Specialists Conference
Regulatory Filings Classification · 1% confidence The document is a press release from Pharnext announcing its support and participation in a medical conference related to Charcot-Marie-Tooth disease (CMT). It details the conference, the company's involvement, and provides an update on its lead candidate PXT3003, including the expected timeline for Phase III results (Q4 2023). This type of announcement, which communicates company activities, scientific engagement, and pipeline updates outside of mandatory financial reporting periods (like 10-K or ER), typically falls under general investor relations communication. Since it is not a formal financial report (10-K, IR, ER), a specific legal filing (LTR, DIRS), or a presentation (IP), the most appropriate general category for this type of corporate/investor news release is 'Regulatory Filings' (RNS) as a catch-all for non-standard announcements, or potentially 'Investor Presentation' (IP) if it were a slide deck, but here it is a news release. Given the options, RNS serves as the best fit for a general corporate announcement that isn't explicitly defined elsewhere, although it is highly specific corporate news. It is not an Earnings Release (ER) or Interim Report (IR) as it focuses on conference participation, not financial results. It is not a Director's Dealing (DIRS) or a Capital Update (CAP). Therefore, RNS is the most suitable fallback for this specific corporate news release.
2023-06-08 English
Pharnext soutient et participe à la Première Conférence Européenne des spécialistes de la maladie de Charcot-Marie-Tooth
Regulatory Filings Classification · 1% confidence The document is a press release dated June 8, 2023, announcing Pharnext's support and participation in the First European Conference for Charcot-Marie-Tooth disease specialists. It details the company's ongoing clinical trial (PREMIER) for its drug candidate PXT3003 and provides general company information. This type of announcement, focusing on participation in an industry event, scientific updates, and general corporate news, does not fit the specific definitions for financial reports (10-K, IR, ER), capital actions (CAP, SHA), or governance filings (DEF 14A, CGR). Since it is a general corporate announcement that doesn't fit a more specific category like Investor Presentation (IP) or Earnings Release (ER), and it is not a short announcement pointing to a larger report (RPA), the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous official announcements.
2023-06-08 French
Point sur le financement Pharnext : levée de fonds de 0,5 million d'euros, réduction drastique du recours aux lignes de financement et fort soutien de Néovacs
Capital/Financing Update Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and details a specific financial transaction: a fundraising effort of 0.5 million euros via the issuance of OCEANE-BSA instruments, alongside updates on existing financing lines (Global Tech Opportunities 13 and Néovacs). This content directly relates to the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER) focusing on operational results, or a simple announcement of a report (RPA). The document is a substantive announcement about financing.
2023-06-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.